October 03, 2019 (New York, NY) — RYAH Medtech Inc. (“RYAH” or the “Company”), announced today that it has signed an agreement with Cannatrek Medical Pty Ltd, a fully licensed Australian company operating as a first mover in the emerging medical cannabis industry, to distribute RYAH dose-measuring dry herb vaporizers and RYAH proprietary dry herb cartridges in Australia.

The partnership agreement will provide RYAH devices and cartridges to patients in Australia with Cannatrek filling, sealing and distributing the dry-herb cartridges with its proprietary strains. The agreement provides both RYAH and Cannatrek the ability to distribute Cannatrek’s dry-herb biomass in a dose-control delivery solution, while collecting HIPAA compliant data analytics throughout the seed to consumption cycle.

“We are pleased to enter the Australian market by signing a strategic partnership with Cannatrek,” said Gregory Wagner, CEO of RYAH Medtech, Inc. “Cannatrek is one of the largest medical plant producers in Australia. Partnering with an industry leader so soon after commercially launching our vaporizers demonstrates the value of our products to the medical plant industry and affirms our commitment to global expansion. This strategic partnership advances our ambitions to provide safe, controlled, plant based regimens, along with AI- powered data analytics, to the medical plant industry. We will continue to build strategic relationships that will expand distribution of our precise dose-measuring delivery devices and accelerate our growth.”

Tommy Huppert, CEO of Cannatrek, said, “As a provider of pioneering plant-based medical treatments, we are committed to supporting safe usage of our products and optimizing treatment outcomes. RYAH’s dry herb vaporizers offer unique benefits to patients, such as enabling them to set limits on how much they inhale, track their usage in real time, record how they feel after each session, and review their stats over time. This means that patients receive precise and predictable results and can better monitor the impact of their treatments

page2image11325088page2image11332992